home genetic news bioinformatics biotechnology literature journals ethics positions events sitemap


UBBFriend: Email This Page to Someone!
  HUM-MOLGEN
  Biotechnical requests and sources
  AnaSpec offers Custom Hybridoma Development

Post New Topic  Post A Reply
profile | register | preferences | faq | search

next newest topic | next oldest topic
Author Topic:   AnaSpec offers Custom Hybridoma Development
anaspec
Member
posted 10-08-2012 06:27 PM     Click Here to See the Profile for anaspec   Click Here to Email anaspec     Edit/Delete Message Reply w/Quote
Leveraging our world-class peptide synthesis expertise and antibody production experience, AnaSpec, EGT Group is pleased to offer high quality custom monoclonal antibody services to the research community and pharmaceutical industry. We have the capabilities to raise monoclonal antibodies to difficult antigens, including peptide sequences that contain post-translational modifications.
• Consultation in peptide antigen design
• Peptide antigens with post-translational modifications can be made
• Flexible protocol and schedule based on customer’s needs
• Immunization time frame of four to eight weeks
• Up-to-date report and customer validation following each project step
• Accessible technical support with expertise in antibody production
• Resources and technical proficiency to work with customer on unconventional projects
Our routine production of monoclonal antibodies is comprised of three phases (Phase I – III). Customers only pay for each phase that is successfully completed. Phase IV, large-scale production of monoclonal antibodies, is optional and available as a stand-alone purchase. Details of each phase are shown below.
Phase I: Antigen Preparation and Immunization (~8-9 weeks)
• Design and production of synthetic peptide antigens with or without modifications
• Site-directed conjugation of peptide antigens to carrier proteins (e.g., KLH and BSA) for flexibility in antigen presentation
• Preparation of peptide and protein antigens with adjuvants for immunization
• Initial and boost immunizations of at least four animals
• Serum separation, ELISA testing and customer consultation before proceeding to Phase II
Phase II: Fusion and Selection of Parental Clones (~3 weeks)
• Splenocytes are harvested for cell fusion from mice with the highest titer
• Clones of fused cells are expanded and screened by ELISA.
• Supernatants, from up to ten ELISA-positive parental clones, are shipped to customer for further antibody testing in immunoassays
• The best parental clones (up to three) are chosen for Phase III after customer consultation
Phase III: Subcloning and selection of Single Clones (~3 weeks)
• Parental clones are sub-cloned by limiting dilution to isolate single clones
• Isotype determination of single clones – IgG subtype guaranteed single clones are expanded and screened by ELISA
• Single clones with high specificity (e.g., phospho vs. non-phospho) and antibody titer will be expanded and cryopreserved
• Three hybridomas, and their supernatants, will be shipped to customer
Phase IV: Large-Scale Production of Monoclonal Antibodies (optional) (~3-6weeks)
• In vivo ascites or in vitro Bioreactor antibody production is available
• Purification of monoclonal antibodies by affinity chromatography using Protein G or with the immunizing peptide antigen
• ELISA and SDS-PAGE are done to validate the purity of the antibody
• AnaSpec offers a range of production scales with flexible cost adjustment
In addition to our custom services, AnaSpec, EGT Group offers popular catalog monoclonal antibodies such as the anti-amyloid (1-40) and (1-42) antibodies.
For more information, please visit http://www.anaspec.com/products/promotions.asp?id=105&col=1&row=1

IP: 12.169.96.11

All times are ET (US)

next newest topic | next oldest topic

Administrative Options: Close Topic | Archive/Move | Delete Topic
Post New Topic  Post A Reply
Hop to:

Contact Us | HUM-MOLGEN

Copyright by HUM-MOLGEN 1995-2015

Powered by: Ultimate Bulletin Board, Version 5.44a
© Infopop Corporation (formerly Madrona Park, Inc.), 1998 - 2000.